Abstract: The present invention relates to recombinant rat kidney glutathione synthetase. This enzyme can be used to prepare glutathione analogs, and to raise antibodies against glutathione synthetase.The present invention further relates to a DNA molecule encoding rat kidney glutathione synthetase. The DNA molecule is useful for detecting the presence of the glutathione synthetase gene in animals, and for modifying cell and mammal glutathione production. The DNA molecule can also be used to construct models for evaluation of potential therapies.

Abstract: The present invention is directed to isolated nucleic acid molecules encoding mammalian 5-oxoprolinase (m 5-OPase). Expression vectors and host cells comprising the nucleic acid molecules are also provided, as well as methods for increasing or decreasing the expression of m 5-OPase in host cells. The invention further provides a method of screening a substance for the ability of the substance to modify m 5-OPase function, and a method for isolating other m 5-OPase molecules. DNA oligomers and antibodies specific for m 5-OPase are provided, each of which can be used to detect m 5-OPase in a sample.

Abstract: This invention relates to substantially pure diloweralkyl esters of glutathione and the use of these components to increase intracellular levels of glutathione.

Abstract: The nucleotide cDNA sequence for the light subunit of gamma glutamylcysteine synthetase, and the amino acid sequence for this subunit, are disclosed

Abstract: This invention relates to certain S-substituted homocysteine sulfoximines and their uses. Buthionine sulfoximine (BSO) appears to have significant uses for chemotherapy and radio therapy, especially combination chemotherapy and radiation therapy and for treatment of subjects with parasitic infections. The compounds of the invention have the same above-mentioned utilities as BSO but have one or more superior attributes when compared to BSO.

Abstract: The preparation and use of N-acyl glutathione monoalkyl esters to provide increased intracellular levels of glutathione or glutathione equivalents, e.g. N-acyl glutathione or glutathione monoalkyl esters.

Abstract: Substantially pure alkyl monoesters of glutathione, the ester being of the glycine carboxylic acid, and use thereof to increase cellular levels of glutathione.

Abstract: Substantially pure alkyl monoesters of glutathione, the ester being of the glycine carboxylic acid, and use thereof to increase cellular levels of glutathione.

Abstract: The present invention relates to a method for combatting renal toxicity due to metals or nephrotoxic drugs. More specifically, the present invention relates to the administration of gamma-glutamyl amino acids to a subject so as to combat renal toxicity due to metals or nephrotoxic drugs. The present invention also relates to a method for selectively modulating in vivo formation of leukotriene types comprising administering gamma-glutamyl amino acids to a subject.

Abstract: Substantially pure alkyl monoesters of glutathione, the ester being of the glycine carboxylic acid, and use thereof to increase cellular levels of glutathione.

Abstract: L-2-oxothiazolidine-4-carboxylate, a sulfur analog of 5-oxoproline, is cleaved by the enzyme 5-oxo-L-prolinase to form cysteine, thus providing the basis for a cysteine delivery system by the addition of L-2-oxothiazolidine-4-carboxylate to base amino acid solutions or by injecting it directly into in vivo cells.

Abstract: L-2-oxothiazolidine-4-carboxylate, a sulfur analog of 5-oxoproline, is cleaved by the enzyme 5-oxo-L-prolinase to form cysteine, thus providing the basis for a cysteine delivery system by the addition of L-2-oxothiazolidine-4-carboxylate to base amino acid solutions or by injecting it directly into in vivo cells.

Abstract: L-2-oxothiazolidine-4-carboxylate, a sulfur analog of 5-oxoproline, is cleaved by the enzyme 5-oxo-L-prolinase to form cysteine, thus providing the basis for a cysteine delivery system by the addition of L-2-oxothiazolidine-4-carboxylate to base amino acid solutions or by injecting it directly into in vivo cells.

Abstract: L-2-oxothiazolidine-4-carboxylate, a sulfur analog of 5-oxoproline, is cleaved by the enzyme 5-oxo-L-prolinase to form cysteine, thus providing the basis for a cysteine delivery system by the addition of L-2-oxothiazolidine-4-carboxylate to base amino acid solutions or by injecting it directly into in vivo cells.

Abstract: L-2-oxothiazolidine-4-carboxylate, a sulfur analog of 5-oxoproline, is cleaved by the enzyme 5-oxo-L-prolinase to form cysteine, thus providing the basis for a cysteine delivery system by the addition of L-2-oxothiazolidine-4-carboxylate to base amino acid solutions or by injecting it directly into in vivo cells.